Óleo de peixe com ômega-3 mostra potencial contra diabetes tipo 2 não obeso

Um estudo brasileiro constatou que suplementos de óleo de peixe reduziram a resistência à insulina e a inflamação em ratos que serviram como modelo de diabetes tipo 2 não obeso. A pesquisa destaca um possível papel dos ácidos graxos ômega-3 em casos nos quais a obesidade não é um fator.

Pesquisadores de instituições como o Instituto Butantan administraram óleo de peixe a ratos Goto-Kakizaki três vezes por semana durante oito semanas. A dose equivalia a 2 gramas por quilograma de peso corporal e continha quantidades específicas de EPA e DHA. Os animais tratados apresentaram menor resistência à insulina, melhor controle glicêmico, redução de marcadores inflamatórios e níveis mais favoráveis de colesterol e triglicerídeos.

Artigos relacionados

Pediatrician assessing overweight children in clinic, highlighting study-recommended early treatment to prevent adult risks like diabetes and hypertension.
Imagem gerada por IA

Study recommends treatment for all children with obesity

Reportado por IA Imagem gerada por IA

A new Karolinska Institutet study finds that children with moderate obesity face higher risks of type 2 diabetes, high blood pressure, and lipid disorders in adulthood, even without apparent risk markers. Researchers urge treatment for all such children.

New research from Yale shows that oleic acid, the main fat in olive oil, accelerated tumor growth in mice prone to pancreatic cancer, while omega-3 fats from fish oil cut disease development by half.

Reportado por IA

A major Spanish clinical trial has shown that a modified Mediterranean diet, combined with calorie restriction, physical activity and professional support, reduced the risk of type 2 diabetes by 31 percent over six years. The findings come from the PREDIMED-Plus study involving nearly 5,000 adults with overweight or obesity.

A large review of cardiovascular outcome trials found that people taking GLP-1 receptor agonists—drugs that include semaglutide (sold as Ozempic)—had a lower risk of major heart-related events than those given placebo. The analysis pooled results from 11 trials involving more than 90,000 participants, with an average follow-up of nearly three years, and reported benefits across patient subgroups including those with and without diabetes.

Reportado por IA

A specially formulated tomato-soy juice lowered several markers of inflammation in adults with obesity after four weeks of daily consumption. The beverage, rich in lycopene and soy isoflavones, outperformed a control tomato juice in a small clinical trial led by researchers at The Ohio State University.

Este site usa cookies

Usamos cookies para análise para melhorar nosso site. Leia nossa política de privacidade para mais informações.
Recusar